Advances in clinical treatment of ovary aging

Hai-xiang SUN,Li-jun DING
DOI: https://doi.org/10.3969/j.issn.1004-3845.2018.03.001
2018-01-01
Journal of reproductive medicine
Abstract:Female fertility decreases earlier than the body physiological senescence,and ovarian reserve remarkable declines from the age of 35.The current diagnosis of ovarian aging is based on age,basal blood level of FSH,inhibin B,anti-mullerian hormone (AMH)and antral follicle count (AFC).According to the severity,ovarian aging can be divided into physiological ovarian aging(NOA),occult premature ovarian insufficiency(OPOI),and premature ovarian insufficiency(POI).The addition of growth hormone(GH),DHEA or coenzyme Q10 to the IVF cycle protocol can partially improve the clinical outcome in patients with physiological ovarian aging.There is no effective treatment for premature ovarian insufficiency at present.Ovarian vitrification combined with in vitro activation contributed to an improved pregnancy outcome in POI patients.Stem cell transplantation for POI patients showed promising application prospect in clinical study.Autologous germline mitochondrial energy transfer(AUGMENT),a kind of method to reverse oocyte aging,can obviously improve the oocyte quality and clinical pregnancy outcome in small-scale clinical trials.This article reviews the clinical diagnosis,pathogenesis and intervention of ovarian aging.
What problem does this paper attempt to address?